Drug intelligence / Profile preview

STC006

Development stage: Unknown
Lead developer: Staidson Biopharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

STC006 is a monoclonal antibody developed by Staidson Biopharmaceutical that targets thymic stromal lymphopoietin (TSLP). TSLP is an epithelial-derived cytokine that plays a critical role in the initiation and persistence of type 2 inflammation, which is central to the pathogenesis of several allergic diseases. By binding to and neutralizing TSLP, STC006 blocks its interaction with the TSLP receptor complex, thereby inhibiting the downstream release of pro-inflammatory cytokines. The drug is currently being evaluated in clinical trials for the treatment of asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and atopic dermatitis.

Targets

TSLP (Thymic stromal lymphopoietin)

Beyond the preview

Go deeper on STC006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STC006.

Explore the full profile